
Opinion|Videos|April 1, 2025
Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment
Jack R. Andrews, MD; Eugene B. Cone MD; and Edwin Posadas, MD, FACP, discuss how early intervention with individualized treatment approaches based on disease volume, patient characteristics, and biomarkers significantly improves survival outcomes in metastatic hormone-sensitive prostate cancer.
Advertisement
Episodes in this series

Timecodes
1:35 Individualized Care for PC
9:24 Frailty & Comorbidities in PC
12:27 Molecular Testing in PC
18:10 Sequencing in PC
22:00 Doublets/Triplets in mHSPC
30:00 Subgroups in mHSPC
39:00 ARASENS Subgroup Analysis
43:55 Future of mHSPC Care
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD
2
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
3
Kari Tikkinen, MD, PhD, discusses POISE-3 findings on tranexamic acid in urologic surgery
4
Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy
5















